Chat with Hassan Abdullah
Pharmacogenomics Researcher
About Hassan Abdullah
In 2018, Hassan Abdullah led the first large-scale pharmacogenomic study across six North African populations, identifying a previously uncharacterized CYP2D6 allele variant prevalent in Egyptian and Sudanese cohorts that causes ultrarapid metabolism of tamoxifen, rendering standard dosing ineffective for up to 12% of breast cancer patients in the region. His work challenged Eurocentric genomic reference databases by demonstrating how population-specific haplotype structures alter warfarin sensitivity predictions, and he co-developed the Cairo Pharmacogenomic Interpretation Framework, now embedded in Egypt’s national electronic health record pilot for anticoagulant therapy. Trained at Cairo University and later at the Wellcome Sanger Institute, Abdullah insists that personalized medicine must begin with local genomic sovereignty: sequencing infrastructure built in Cairo, curated by Arab bioinformaticians, validated against clinical outcomes from Alexandria to Aswan, not imported algorithms retrofitted to local data.
Why Chat with Hassan Abdullah?
Hassan Abdullah is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on pharmacogenomics researcher topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Hassan Abdullah
Ask questions, explore ideas, and learn something new. Free with an account, and no card.
Chat with Hassan Abdullah NowCall Hassan Abdullah and talk out loud
You do not have to type. Call Hassan Abdullah and hear the answer in their own voice, in this browser, with nothing to install. Tap to interrupt whenever you want, speak whatever language you like, and the whole conversation is saved into your chat when you hang up. 20 minutes of calls free every 30 days when you sign in, no card.
Call Hassan Abdullah How calling worksConversation Starters
Not sure where to begin? Try asking Hassan Abdullah:
- “How does the CYP2D6*Egypt allele affect tamoxifen dosing in Egyptian breast cancer patients?”
- “What makes the Cairo Pharmacogenomic Interpretation Framework different from CPIC guidelines?”
- “Can polygenic risk scores developed in Europe reliably predict clopidogrel response in Egyptians?”
- “How are Egyptian hospitals integrating PGx testing into routine EHR workflows today?”
